Hologic, Inc. (NASDAQ:HOLX) Shares Sold by State of Michigan Retirement System

State of Michigan Retirement System reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 63,065 shares of the medical equipment provider’s stock after selling 200 shares during the period. State of Michigan Retirement System’s holdings in Hologic were worth $4,546,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Swedbank AB raised its position in Hologic by 18.8% during the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Hologic by 55.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock worth $607,000 after purchasing an additional 2,645 shares during the period. Stephens Inc. AR increased its holdings in shares of Hologic by 50.8% during the 3rd quarter. Stephens Inc. AR now owns 6,445 shares of the medical equipment provider’s stock valued at $525,000 after purchasing an additional 2,172 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Hologic by 27.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical equipment provider’s stock valued at $164,000 after purchasing an additional 434 shares during the period. Finally, Van ECK Associates Corp purchased a new stake in Hologic during the third quarter worth $725,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 0.7 %

Shares of HOLX opened at $62.50 on Friday. The firm’s fifty day moving average is $68.56 and its two-hundred day moving average is $75.55. The stock has a market cap of $14.02 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $61.70 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Stephens reaffirmed an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday. Leerink Partners lowered Hologic from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Finally, Royal Bank of Canada reduced their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.